-
Article
Open AccessOral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer
Tumor hypoxia is associated with prostate cancer (PCa) treatment resistance and poor prognosis. Pimonidazole (PIMO) is an investigational hypoxia probe used in clinical trials. A better understanding of the cl...
-
Article
Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype
Mutations in the pivotal metabolic isocitrate dehydrogenase (IDH) enzymes are recognized to drive the molecular footprint of diffuse gliomas, and patients with IDH mutant gliomas have overall favorable outcome...
-
Article
Open AccessMultiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities
Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma, and a lethal neurofibromatosis type 1-related malignancy, with little progress made on treatment strategies. Here, we apply a mul...
-
Article
Open AccessTNFα secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy
One of the most prominent features of glioblastoma (GBM) is hyper-vascularization. Bone marrow-derived macrophages are actively recruited to the tumor and referred to as glioma-associated macrophages (GAMs) wh...
-
Article
Open AccessClinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
Meningioma is the most common primary brain tumor. Most meningiomas are benign; however, a subset of these tumors can be aggressive, presenting with early or multiple tumor recurrences that are refractory to n...
-
Article
Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis
In the original publication, corresponding author information missed indicating that Dr. Zadeh.
-
Article
Open AccessEpigenomic, genomic, and transcriptomic landscape of schwannomatosis
Schwannomatosis (SWNTS) is a genetic cancer predisposition syndrome that manifests as multiple and often painful neuronal tumors called schwannomas (SWNs). While germline mutations in SMARCB1 or LZTR1, plus somat...
-
Article
Open AccessProgrammed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression
Management of clinically aggressive meningiomas is a considerable challenge. PD-L1 induced immune suppression has increasingly gained attention in clinical management of cancer; however, to date, the clinical ...
-
Article
Open AccessThe central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care
Molecular signatures are being increasingly incorporated into cancer classification systems. DNA methylation-based central nervous system (CNS) tumor classification is being recognized as having the potential ...
-
Article
Open AccessEpigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-call...
-
Article
Open AccessCIC protein instability contributes to tumorigenesis in glioblastoma
Capicua (CIC) is a transcriptional repressor that counteracts activation of genes downstream of receptor tyrosine kinase (RTK)/Ras/ERK signaling. It is well-established that tumorigenesis, especially in gliobl...
-
Article
Open AccessTherapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas
Cranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. Unfortunately, long-term survivors are faced with consequences of secondary neoplasia, includin...
-
Article
Open AccessProceedings of the 7th Biannual International Symposium on Nasopharyngeal Carcinoma 2015
A1 Hope and despair in the current treatment of nasopharyngeal cancer
-
Article
Glioblastoma: pathology, molecular mechanisms and markers
Recent advances in genomic technology have led to a better understanding of key molecular alterations that underlie glioblastoma (GBM). The current WHO-based classification of GBM is mainly based on histologic...